Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"- oxathiole-2",2"-dioxide] (TSAO)

D Arion, RS Fletcher, G Borkow, MJ Camarasa, J Balzarini, GI Dmitrienko and MA Parniak

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.

We compared the inhibition of HIV-1 reverse transcriptase (RT) by 1- [2',5'-bis-O-(t-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'- spiro-5"- (4"-amino-1", 2"-oxathiole-2",2"-dioxide)-3-ethylthymine (TSAOe3T) and the nonnucleoside RT inhibitor (NNRTI) 9-aminonevirapine (9-NH2N). Both compounds were equally effective against p51/p66 heterodimeric RT RNA- dependent DNA polymerase activity, although TSAOe3T was a much better inhibitor of the p51/p51 and p66/p66 RT homodimers. Inhibition by TSAOe3T and 9-NH2N combinations was essentially additive. TSAOe3T did not protect either free RT or the RT-template/ primer-deoxynucleoside triphosphate ternary complex from irreversible inactivation by the photolabel 9-azidonevirapine. Slight protection of the RT- template/primer binary complex was noted, but only at high TSAOe3T/photolabel ratios. Analysis of RT polymerization product profiles under both continuous- and single-processive cycle conditions showed that 9-NH2N prevented the formation of full-length product with a corresponding accumulation of smaller polymerization products. In contrast, all products formed in the absence of inhibitor, including full-length product, were noted in TSAOe3T-inhibited reactions, albeit at reduced levels. TSAOe3T thus inhibits HIV-1 RT by a different mechanism than NNRTI such as nevirapine. Our data suggest that TSAOe3T and 9-NH2N interact differently with HIV-1 RT, perhaps by binding to distinct sites on the enzyme.

Volume 50, Issue 5, pp. 1057-1064, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Balzarini, J. Auwerx, F. Rodriguez-Barrios, A. Chedad, V. Farkas, F. Ceccherini-Silberstein, C. Garcia-Aparicio, S. Velazquez, E. De Clercq, C.-F. Perno, et al. The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors Mol. Pharmacol., July 1, 2005; 68(1): 49 - 60. [Abstract] [Full Text] [PDF]

				N. Sluis-Cremer, D. Arion, and M. A. Parniak Destabilization of the HIV-1 Reverse Transcriptase Dimer upon Interaction with N-Acyl Hydrazone Inhibitors Mol. Pharmacol., August 1, 2002; 62(2): 398 - 405. [Abstract] [Full Text] [PDF]

				G. Maga, A. Ramunno, V. Nacci, G. A. Locatelli, S. Spadari, I. Fiorini, F. Baldanti, S. Paolucci, M. Zavattoni, A. Bergamini, et al. The Stereoselective Targeting of a Specific Enzyme-Substrate Complex Is the Molecular Mechanism for the Synergic Inhibition of HIV-1 Reverse Transcriptase by (R)-(-)-PPO464. A NOVEL GENERATION OF NONNUCLEOSIDE INHIBITORS J. Biol. Chem., November 21, 2001; 276(48): 44653 - 44662. [Abstract] [Full Text] [PDF]